Skip to main content

Table 3 Study characteristics of the 39 studies which were identified as eligible for the Cochrane review on the cessation efficacy of ECs [14]

From: The potential of new nicotine and tobacco products as tools for people who smoke to quit combustible cigarettes – a systematic review of common practices and guidance towards a robust study protocol to measure cessation efficacy

Sample size

Country

Study type

Study duration

Control groups

Compliance measure

Familiarization

Cessation efficacy measures

BoE/BoPH

Median: 71

Mean: 226

Min-Max: 12-1563

US: 14

Italy: 8

UK: 7

Australia, Greece: 2

Belgium, Canada, New Zealand, Poland, South Korea, Turkey: 1

RCT: 30

Interventional: 9

Cross-sectional: 0

Longitudinal: 0

Median: 4 m

Min-Max: 0.4–24 m

CC: 13

NS: 0

Quitters: 15

CO: 25

CO/Cot: 4

Cot: 1

CO/Cot/AB: 1

CO/Cot/ OHCot: 1

CO/NNAL: 1

16

QBA: 24

Abstinence: 24

Use: 36

PK: 3

28

  1. AB: anabasine; BoE: biomarker of exposure; BoPH: biomarker of potential harm; CC: consumer of combustible cigarettes; CO: carbon monoxide; Cot: cotinine; m: months; Max: maximum; Min: minimum; NNAL: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; NS: never smoker; OH-Cot: trans-3’-hydroxycotinine; PK: Pharmacokinetics of nicotine; QBA: Questionnaire-based assessments; RCT: randomized controlled trial
Back to article page

Harm Reduction Journal

ISSN: 1477-7517